Clinical trial · Interventional
Utilization of Genomic Information to Augment Chemotherapy Decision-making for People With Incurable Malignancies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Most systemic therapies are chosen on the basis of large randomized clinical trials; however, tumour heterogeneity means that cancers with similar histological features may have substantially different underlying biological drivers. The investigators propose that applying personal genomic information prospectively obtained in a clinically realistic timeframe to assist in chemotherapy decision-making could result in more effective and efficient cancer treatment. This study will investigate this approach in a cross section of advanced cancers to examine timeliness, deliverability, rate of actionable targets identified, and our ability to expand this approach into a larger clinical trial setting.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Incurable Cancers | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| in depth genomic sequencing | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Sequenced patients
- description
- Patients enrolled on the study who have successful sequencing of their cancers will be closely monitored for: what chemotherapy agents are next used, what response and toxicity do they have, is there any early sign of response detected on PET-CT, overall did the genomic information change treatment decision-making.
- interventionNames
- Genetic: in depth genomic sequencing
Primary outcomes (1)
- measure
- Frequency of actioanble genomic abnormalites detected that modify treatment
- timeFrame
- up to 24 months
- description
- What is the frequency of "actionable" results in this varied tumour population ?
Secondary outcomes (1)
- measure
- What is the frequency with which these actionable results actually result in a subject receiving a drug(s) related to this test
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Subjects must have histologically or cytologically confirmed diagnosis of cancer 2. This cancer must be incurable, as defined by their treating oncologist (generally because of advanced stage). 3. Subjects must agree to provide archival tissue and agree to undergo a study specific biopsy and blood test for genetic analysis. All subjects would have a biopsy and blood samples at progression if it could be done safely. 4. ECOG PS 0 or 1. 5. Age \> 18 years of age. 6. Subject consent must be obtained according to the BCCA requirements. 7. Subject must be accessible for treatment and follow-up. Subjects must be registered at the BCCA Vancouver site. Exclusion Criteria: 1. Unable or unwilling to undergo tumour biopsy(s) and/or blood/skin samples for normal DNA. 2. Significant medical condition that in the opinion of the treating oncologist renders the subject not suitable for participation.
References
Publications (1)
- BACKGROUNDPeixoto RD; Li Y; Pleasance E; Yip S; et al. A case of the utilization of genomic information in the management of metastatic colorectal cancer. J Clin Oncol 30: 2012 (suppl 34; abstr 444)